风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 根据公司最新披露的2025年半年度报告，上半年实现营业收入12.39亿元，归属于上市公司股东的扣除 非经常性损益的净利润3685.49万元，同比增长36.34%。其中，战略产品"盐酸羟考酮注射液"营业收入 同比增长逾90%，"盐酸纳洛酮注射液"中选第十批国家组织药品集中采购。在研发方面，公司多个药品 上市许可申请获得国家药监局受理。 8月26日，中关村主力资金净流入399.25万元，近五个交易日累计净流入1691.89万元。 截至2025年8月26日15时，中关村最新股价为5.63元，较前一交易日上涨0.36%。当日开盘价为5.58元， 最高触及5.67元，最低下探5.55元，成交量为20.24万手，成交金额达1.14亿元。 中关村所属化学制药板块，公司主营业务涵盖生物医药及健康品、商砼、养老医疗三大领域。作为北京 地区医药企业，公司拥有盐酸贝尼地平片、盐酸羟考酮注射液等核心产品，并布局创新药研发。 ...

8月25日午间，石四药集团在港交所公告，集团已取得中国国家药监局有关盐酸贝尼地平片（8mg）的 药品生产注册批件，属于化学药品第4类，视同通过一致性评价。盐酸贝尼地平片主要用于治疗原发性 高血压和心绞痛。 ...

Core Insights - The establishment of a "drug unavailability" service window in Qingpu District addresses the issue of residents, particularly the elderly and chronic disease patients, facing difficulties in obtaining necessary medications at local health clinics [1][2] - The initiative has successfully resolved nearly a hundred cases of drug shortages, with over 90% of these related to chronic disease medications, achieving a 100% satisfaction rate among residents [1][2] Summary by Sections - **Service Implementation**: Since April, Qingpu District has introduced a dedicated service window for residents to report difficulties in obtaining medications, allowing for a more efficient drug delivery system [1][2] - **Challenges Addressed**: The service aims to tackle the limited drug availability in rural areas, exacerbated by an increasing number of chronic disease patients and the elderly population [2] - **Resource Optimization**: The initiative is designed to prevent resource waste by ensuring that community health service centers maintain a variety of medications without overstocking in individual village clinics that may serve only a small number of residents [2] - **Drug Availability Statistics**: Currently, over 80% of medications available in tertiary hospitals can be found in community health service centers, with plans to further enhance this ratio through improved coordination within the medical service network [3]

Core Viewpoint - The company has received the drug registration certificate for Benidipine Hydrochloride Tablets (8mg) from the National Medical Products Administration, which will enhance its product line and market competitiveness [1] Group 1: Drug Approval and Market Impact - The drug was first approved in Japan in 1991 and received domestic approval in 2004 for the treatment of primary hypertension and angina [1] - The company received the acceptance notice for the application on March 5, 2024, and has recently been granted approval [1] - The estimated sales revenue for Benidipine Hydrochloride Tablets in China's three major terminal markets is approximately 1.007 billion yuan in 2024 [1] Group 2: R&D Investment - The total research and development investment for this drug by the company amounts to 5.2737 million yuan [1]

Summary of Key Points Core Viewpoint - The company, Hunan Warner Pharmaceutical Co., Ltd., is adjusting and postponing certain fundraising investment projects to enhance the efficiency of fund utilization and align with market conditions and internal project progress [1][18]. Fundraising Investment Project Overview - The company raised a total of RMB 723.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related fees [1][2]. - The funds are stored in a special account, and a tripartite supervision agreement has been signed among the company, the sponsor, and the bank [2]. Fund Usage Status - As of May 31, 2025, the cumulative investment in the high-end raw material drug production base construction project (Phase I) is RMB 414.01 million, with a total investment of RMB 655.65 million [3][4]. - The company has completed the Phase I project and transferred surplus funds to supplement working capital [3][5]. Adjustments and Postponements - The company has decided to reduce the funding for the traditional Chinese medicine preparation and quality testing center project from RMB 94.28 million to RMB 29.28 million and extend the project duration from two to three years [5][13]. - Surplus funds from completed projects will be redirected to ongoing and new projects, optimizing the allocation of resources [13][18]. R&D Focus and Future Plans - The company aims to enhance its product pipeline in various therapeutic areas, including respiratory, analgesic, cardiovascular, and neurological systems, with a focus on innovative drug development [10][11]. - Specific funding allocations include RMB 47.6 million for respiratory products and RMB 47.8 million for analgesic products [10][11]. Feasibility Analysis - The company has established core technology platforms and a strong R&D team to support ongoing projects, ensuring the capability to meet future development needs [17][18]. - The adjustments made are in line with the company's strategic planning and operational requirements, aiming to capture market opportunities without adversely affecting normal operations [18][19].